Sea Pharmaceuticals has filed a notice of an exempt offering of securities to raise $2,175,701.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Sea Pharmaceuticals is raising $2,175,701.00 in new funding. Sources indicate that as part of senior management President, James Pearson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Sea Pharmaceuticals
Privately held central nervous system (CNS) focused therapeutics company founded in March 2013 by biologist and pharmacologist James P. Pearson PhD (JPP) and medicinal chemist/ process chemist Eduardo J. Martinez PhD based in Cambridge MA, USA. Sea is working on discovery, research, development (R&D) and commercialization of novel proprietary synthetic small molecules as innovative treatment of the devastating neurological disease Sporadic ALS (Amyotrophic Lateral Sclerosis) and other CNS indications. Sea works with a network of Key Opinion Leaders in neuroscience, pharmacology and chemistry.
To learn more about Sea Pharmaceuticals, visit http://www.seapharmaceuticals.com/
Contact:
James Pearson, President
617-794-9578
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.